Cambrian

Building therapeutics to treat and prevent today’s most debilitating chronic diseases.

[Cambrian @CambrianBio]

We’re excited to announce that we will be presenting data from two Phase 1 studies of ATX-304 at @ObesityWeek 2026, The Obesity Society’s 44th Annual Meeting.

ATX-304 is the first AMPK Network Activator to enter clinical development. Building on clinical results first presented at ADA earlier this year, our poster will show the dose- and time-dependent effects of ATX-304 on lipids, adipose tissue, and energy expenditure.

• Poster-111, Exhibit Hall BCD
• Saturday, November 14, 7:30–8:30 PM ET
• Session: Translational Research & Emerging Metabolic Therapies

Read the full release: https://t.co/swgQhy2NmS

[Cambrian @CambrianBio]

Another outstanding ARDD meeting in the books!

On the Main Stage, our CEO @JamesPeyer presented “Reversing metabolic decline through AMPK Network Activation in humans,” sharing data on our lead asset, ATX-304, an AMPK Network Activator in clinical development for obesity and other forms of cardiometabolic disease.

At the poster sessions, our Director, R&D Project Management, Travis McQuiston, PhD, presented our TORnado platform of highly selective mTORC1 inhibitors.

Our CFO/COO, Juliette Han, PhD, and Chief Business Officer, Mark Nuttall, were also in attendance, connecting with colleagues across the field and taking in the week’s science.

Thank you to the @ARDD_Meeting team for another great event, and thank you to everyone who stopped by to connect. More to come!

[Cambrian @CambrianBio]

We are proud to sponsor the 13th @ARDD_Meeting at Harvard's David Rubenstein Treehouse, and thrilled to share that our CEO, @JamesPeyer, will be speaking.

James will present "Reversing metabolic decline through AMPK Network Activation in humans" on the Main Stage on Saturday, October 3 at 3:10 PM ET.

While you're there, visit the poster sessions to meet Travis McQuiston, PhD, our Director, R&D Project Management, and learn more about our TORnado platform of highly selective mTORC1 inhibitors.

See the full program and register: https://t.co/ASO8MtEnIP

#ARDD2026

[Brent Saunders @brentlsaunders]

@Markis @rapalogix @DrDorisDay I failed to mention the founders also include @JamesPeyer We couldn’t have done it without him!

[Cambrian @CambrianBio]

Weight loss is not the only goal of weight-loss medication. Many patients also want to walk farther, move more, and stay physically independent.

In our latest blog, our team explores important questions that remain regarding the effects of GLP-1 therapies on physical activity, fitness, and functional ability, and why the field may need to look beyond the scale to define treatment success. Read more: https://t.co/wHJqu4W2dj

[Cambrian @CambrianBio]

https://t.co/wdxjU69zil

[Cambrian @CambrianBio]

Muscle is a key metabolic organ, and as GLP-1-based therapies reshape obesity treatment, a new clinical question is emerging: how do we ensure weight loss doesn't come at the expense of muscle?

In our latest blog, our team explores why muscle preservation matters for long-term metabolic health, physical function, and healthy aging, and which patient populations may be most vulnerable. Read more: https://t.co/aHKnpYPwPJ

#metabolism #metabolichealth #glp1

[Cambrian @CambrianBio]

A thoughtful provocation in Nature Aging by our CEO @JamesPeyer: are GLP-1 receptor agonists gerotherapeutics, or are they just treatments for obesity?

It's a question worth sitting with. The answer shapes how we design drugs, define patient populations, and ultimately measure success in a field that's still working out what it means to treat aging itself.

Read the full publication here: https://t.co/dBuOpOb3mU

[James Peyer @JamesPeyer]

https://t.co/asTGclFl1D

[Cambrian @CambrianBio]

We're thrilled to announce positive Phase 1b clinical data for ATX-304, the first AMPK Network Activator to enter clinical development, presented at the American Diabetes Association's 86th Scientific Sessions.

For the first time, we have demonstrated activity of an AMPK Network Activator in humans, with statistically significant improvements in liver fat, visceral adipose tissue, triglycerides, adiponectin, and resting metabolic rate in adults with obesity and prediabetes.

The overall tolerability profile was comparable to placebo, with no adverse events indicative of mitochondrial failure, including no increase in continuously monitored core body temperature or 24-hour heart rate. A companion mechanistic poster confirmed that ATX-304 activates AMPK without decreasing cellular ATP levels, distinguishing it from prior AMPK-targeting approaches.

We look forward to advancing ATX-304 into Phase 2 studies REWIRE-1 and REWIRE-2, evaluating exercise mimetic effects and muscle-sparing weight loss.

Read the full release: https://t.co/YSbpoK7U0z

[Cambrian @CambrianBio]

Happening today ‼️

@TheEndoSociety

[James Peyer @JamesPeyer]

This weekend I'm headed to the @TheEndoSociety conference in SF where we've been invited to give an oral presentation.

I’ll be sharing with the world for the first time the ability of our lead drug, ATX-304 to 🧵👇

[Cambrian @CambrianBio]

This Sunday, 7/13‼️Our CEO @JamesPeyer is headed to @TheEndoSociety to present new data on the efficacy of ATX-304, our lead drug. Check out the press release to learn more 👇

https://t.co/dykERwYSwT

[James Peyer @JamesPeyer]

One of the most hollow critiques of translating discoveries about aging biology – “they will only be for the rich.”

Demand curve says no. Preventative medicines are cheaper than other drugs and these will be among the best preventatives of all time.
https://t.co/KGeOLdukKE

[James Peyer @JamesPeyer]

This newsletter is meant to be my own thinking and I try to be a bit more provocative here, so the views I express might not always reflect the position of @CambrianBio, which is much larger than me alone.
https://t.co/DTJWKjxwXM

[Cambrian @CambrianBio]

You can learn more about the historical disparities of women’s health on the @OvivaTx website. While you're there, be sure to explore the incredible work they're doing to improve women’s health through groundbreaking biomedical research! https://t.co/d3Ds4Ekahg

[Cambrian @CambrianBio]

Happy International Women’s day! Here are some fun facts about women’s health 👇

[Cambrian @CambrianBio]

But today, as we celebrate women and the progress made, let's remember that our work isn't done. We must continue pushing for a future where women's health is prioritized, ensuring that every woman receives the care she deserves.

[Cambrian @CambrianBio]

While we don't endorse chasing people down for snacks, our goal is to enable everyone to live as Dyna-Mitally through later years! 😉 #DinamitaDinero